Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Other Non-Current Liabilities (2021 - 2025)

Rxo (RXO) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $69.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 16.87% year-over-year to $69.0 million, compared with a TTM value of $69.0 million through Dec 2025, down 16.87%, and an annual FY2025 reading of $69.0 million, down 16.87% over the prior year.
  • Other Non-Current Liabilities was $69.0 million for Q4 2025 at Rxo, down from $71.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $88.0 million in Q1 2025 and bottomed at $36.0 million in Q3 2022.
  • Average Other Non-Current Liabilities over 5 years is $52.9 million, with a median of $41.0 million recorded in 2024.
  • Peak annual rise in Other Non-Current Liabilities hit 114.63% in 2025, while the deepest fall reached 16.87% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $37.0 million in 2021, then increased by 8.11% to $40.0 million in 2022, then changed by 0.0% to $40.0 million in 2023, then skyrocketed by 107.5% to $83.0 million in 2024, then dropped by 16.87% to $69.0 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for RXO at $69.0 million in Q4 2025, $71.0 million in Q3 2025, and $70.0 million in Q2 2025.